Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, ...

A study published in the Journal of Controlled Release ("NMR-based analysis of impact of siRNA mixing conditions on internal structure of siRNA-loaded LNP"), led by Assistant Professor Keisuke Ueda ...

Ribo Life Science Co., Ltd. ('Ribo' or the 'Company', stock code: 06938.HK), a leading company in small interfering RNA ...

Generation Bio Co. is developing siRNA therapeutics for T cell-driven autoimmune diseases using its T cell-selective lipid nanoparticle technology. This innovative delivery system aims to effectively ...

In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, in Sweden in 2022 to engage in research activities. That move gives the ...

Bayer & Soufflé Therapeutics enter strategic collaboration to advance cell-specific heart-targeted siRNA therapy: Berlin, Germany Friday, January 9, 2026, 09:00 Hrs [IST] Bayer a ...